The strong revenue growth and independent validation of cost savings support commercial momentum; traders should monitor the May 14 earnings release for confirmation of these preliminary figures and any updates on system placements.
Price Chart
Executive Summary
IceCure Medical announced preliminary, unaudited U.S. ProSense revenue growth of over 30% in Q1 2026 compared to Q1 2025, driven by FDA clearance for low-risk breast cancer treatment and increased adoption at major hospitals. The news coincides with the company's participation in the Society of Breast Imaging Symposium, where a cost analysis study showed cryoablation could reduce treatment costs by over 50% versus surgery.
Key Facts
- U.S. ProSense revenue increased over 30% in Q1 2026 vs. Q1 2025 (preliminary, unaudited)
- Growth follows FDA clearance in October 2025 for low-risk breast cancer treatment in women aged 70+
- Massachusetts General Hospital study presented at SBI 2026 showed cryoablation reduces costs by over 50% vs. lumpectomy
- Company expanding installed base at leading U.S. academic and research hospitals
- Full financial results expected May 14, 2026
Financial Impact
Over 30% year-over-year revenue growth in the U.S. market for ProSense systems and cryoprobes
Risk Factors
- Preliminary revenue figures are unaudited and subject to final adjustments
- Forward-looking statements are subject to risks including funding availability, regulatory developments, and market adoption
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-045896 |
| Document: ea0286976-6k_icecure.htm | 0001213900-26-045896 |
| Document: 0001213900-26-045896-index-headers.html | 0001213900-26-045896 |
| Document: 0001213900-26-045896-index.html | 0001213900-26-045896 |
| Document: 0001213900-26-045896.txt | 0001213900-26-045896 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 6-K | $1.10 | awaiting T+60 | — | $1.03 (−6.36%) |
Oct 5, 2026 21d ago | 6-K | $1.27 | awaiting T+60 | — | $1.03 (−18.90%) |
Oct 5, 2026 21d ago | 6-K | $1.54 | awaiting T+60 | — | $1.03 (+33.12%) |
Sep 10, 2026 6w ago | 6-K | $2.14 | awaiting T+60 | — | $1.03 (−51.87%) |
Aug 24, 2026 9w ago | 6-K | $2.27 | awaiting T+60 | — | $1.03 (−54.63%) |
Aug 19, 2026 9w ago | EFFECT | $2.52 | awaiting T+60 | — | $1.03 (+59.13%) |
Aug 14, 2026 10w ago | 6-K | $2.82 | awaiting T+60 | — | $1.03 (−63.48%) |
Aug 12, 2026 10w ago | 6-K | $3.11 | awaiting T+60 | — | $1.03 (−66.83%) |
Jul 6, 2026 16w ago | EFFECT | $4.61 $1.59 | ▲ +65.51% | ▲ +67.23% | $1.03 (+77.66%) |
Jun 26, 2026 17w ago | 6-K | $5.26 $1.95 | ▲ +62.93% | ▲ +67.31% | $1.03 (+80.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers